Literature DB >> 9576162

Long-term follow-up of rheumatic patients undergoing left-sided valve replacement with tricuspid annuloplasty--validity of preoperative echocardiographic criteria in the decision to perform tricuspid annuloplasty.

R Tager1, D Skudicky, U Mueller, R Essop, G Hammond, P Sareli.   

Abstract

Between September 1989 and December 1991, modified De Vega tricuspid annuloplasty was performed in 43 patients who survived surgery for mitral or mitral plus aortic valve replacement. The preoperative indications for tricuspid annuloplasty were moderate to severe tricuspid regurgitation (TR) in 33 patients and mild or no TR but with a dilated tricuspid annulus (> or =30 mm) as measured by 2-dimensional echocardiography at end-diastole in 10 patients. The mean age was 31 +/- 13 years. The mean duration of follow-up was 57 +/- 18 months. Overall long-term mortality was 12%. On Doppler color flow mapping, postoperative severe TR was present in 1 patient and moderate TR in 4 patients at latest follow-up. The tricuspid annulus diameter decreased from 37 +/- 5 mm preoperatively to 24 +/- 6 mm at latest follow-up. During the study period, an additional 77 patients underwent mitral valve replacement or double valve replacement, but without tricuspid annuloplasty. Within this group, 38 patients had a preoperative tricuspid annulus diameter of > or =30 mm, and 5 of these patients (13%) developed moderate or severe TR in the postoperative period, which may have been prevented had clinicians adhered to the preoperative indications for tricuspid annuloplasty. Thus, preoperative echocardiographically documented moderate or severe TR or a tricuspid annulus diameter of > or =30 mm are valid indications for performing tricuspid annuloplasty; modified De Vega tricuspid annuloplasty is a durable procedure in rheumatic patients; it appears that reducing the diastolic tricuspid annulus diameter to 24 mm is adequate to prevent residual TR in the long term.

Entities:  

Mesh:

Year:  1998        PMID: 9576162     DOI: 10.1016/s0002-9149(98)00081-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Tricuspid regurgitation: pathophysiology and management.

Authors:  Rashmi Thapa; Buddhadeb Dawn; Jayant Nath
Journal:  Curr Cardiol Rep       Date:  2012-04       Impact factor: 2.931

2.  Predictors of secondary tricuspid regurgitation after left-sided valve replacement.

Authors:  Guohua Wang; Zongquan Sun; Jiahong Xia; Yongzhi Deng; Jiajun Chen; Gang Su; Youli Ke
Journal:  Surg Today       Date:  2008-08-28       Impact factor: 2.549

Review 3.  Evidence-based surgical management of acquired tricuspid valve disease.

Authors:  Sung Ho Shinn; Hartzell V Schaff
Journal:  Nat Rev Cardiol       Date:  2013-02-12       Impact factor: 32.419

4.  Tricuspid Valvular Regurgitation.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-02

5.  [Surgical treatment of tricuspid regurgitation associated with left valvular heart disease: about 162 cases].

Authors:  Amine Majdoub; Salaheddine Boulmakoul; Anas Elhafidi; Mohammed Messouak
Journal:  Pan Afr Med J       Date:  2021-12-23

6.  Severe tricuspid regurgitation after mitral valve surgery: the risk factors and results of the aggressive application of prophylactic tricuspid valve repair.

Authors:  Hiroshi Takano; Miyoko Hiramatsu; Hirota Kida; Mitsuru Uenoyama; Kei Horiguchi; Takashi Yamauchi; Keiwa Kin; Yukitoshi Shirakawa; Mitsunori Kaneko; Takashi Daimon
Journal:  Surg Today       Date:  2016-08-08       Impact factor: 2.549

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.